Severe muscle weakness seriously affects patients' daily life and work, and urgently needs to improve their treatment ending and quality of life

Severe muscle weakness is a rare, chronic autoimmune disease, which is caused by neurological-muscle joints to transmit dysfunctional dysfunction. Long course, difficulty cure, and recurrence. In 2018, it has been included in my country's "The First Batch of Rare Diseases". It is estimated that at least 200,000 patients with severe severe muscles in my country. If the symptoms are not controlled, the weakness of the intensive muscles will seriously affect the daily life and work of patients, reduce the ability and quality of life, and bring a heavy burden on families and society.

It is understood that more than 85%of adult -type intensive muscle weakness patients will progress to systemic intensive muscle weakness within 18 months, which can affect the patient's eyeballs, swallowing, speech, activity, and respiratory function to varying degrees. life threatening. Every year on June 15th is the day of severe muscle weakness. At this time, the launching ceremony of severe diseases and urgent need for severe muscles is held in Haikou. The world's first FCRN antagonist Efgartigimod successfully landed It is referred to as the Lecheng Pioneer Zone), which has become a new breakthrough of severe drug weakness drugs in my country in the past 30 years, and has rewritten domestic severe muscle weakness.

Jia Ning, director of the Lecheng Pioneering District Management Bureau, said that as a key park in the construction of Hainan Free Trade Port, the Ledong Pioneer District has basically realized the simultaneous introduction of international innovative drugs and the access to drugs, entering a new stage of high -quality development Essence In the field of rare diseases, Locheng has been committed to improving the efficiency of the introduction of rare diseases, and providing integrated services from drug introduction, approval to treatment for patients with rare diseases. I am very happy to introduce the international frontier innovation treatment plan for patients with severe muscle weaknesses to change the dilemma of "no medicine available in domestic medicine" in domestic severe muscle weakness.

"Thanks to the franchise policies given to Lecheng by the State Council, the Provincial Pharmaceutical Regulatory Bureau approved the introduction of international innovative drugs that were introduced by Zaiding Pharmaceutical and the treatment of intensive muscle weakness in Lecheng, which brought new hope to domestic severe patients with weakness. "Zhu Ning, director of the Hainan Provincial Pharmaceutical Bureau, said that in the four years since the implementation of the franchise policy, the Hainan Provincial Drug Administration has continuously expanded the applicability and benefit of the franchise policies, continued to promote the speed of the approved of franchised drugs Department, continuously improve the supervision system, optimize the approval model, and strengthen the effectiveness of supervision, ensure that there are more types of franchise supplies, wider coverage, stronger product innovation, greater value in clinical needs, greater value in clinical clinical use in my country. As of the same way, as of now, the first case of special medicines for the imported special medicines imported by Locheng has exceeded 220 species.

Professor Chen Tao, deputy dean of the People's Hospital of Hainan Province, said that he hopes to use Efgartigimod to land in Locheng to help build the Hainan regional intensive muscle weak treatment platform and alliance, and then create new possibilities for patients with severe muscle weakness in Hainan and the whole country, and for domestic severe illness Somoscope clinical treatment opens a new door.

At present, the most common treatment schemes of intensive muscle weakness include chiloine inhibitors, glucocorticoids, immunosuppressants, venous injection of immunoglobulin, plasma replacement, anti -CD20 monoclonal resistance, and thymus resection. Professor Zhao Chongbo, chief physician of the Department of Neurology, Affiliated to Fudan University, pointed out that the disease management of patients with severe muscle weakness is difficult. Some patients in clinical clinical problems have caused symptoms control due to drug efficacy, tolerance, contraindications, and poor drugs and poor drugs. Good and repeated fluctuations will also be plagued by side effects due to long -term use of immunosuppressive drugs. In addition, the individualization of patients with severe muscle weakness is large, and the course of disease is different. There are certain percentage of patients with a certain percentage of patients and potential development into crisis. This time EFGARTIGIMOD landing in Lecheng, which provides innovative treatment solutions for clinicians and patients with weak effects, long -term efficacy, and excellent safety. Ending and quality of life.

According to Professor Huang Shixiong, director of the Department of Neurology of the People's Hospital of Hainan Province, Efgartigimod, the world's first innovative drug, introduced Licheng, has become a new breakthrough in my country for 30 years. As a rare disease, the treatment of intensive muscle weakness involves multiple disciplines. In order to accept new drug treatment smoothly and safely, patients have established specialized medical groups including neurology, emergency department, ICU, etc., and and other specialized medical groups, and we have The well -known experts in the field of neurology have established a special long -range multidisciplinary consultation mechanism to maximize the quality of medical treatment for patients with severe muscle weakness.

In addition, Tian Xiaoli, deputy director of the Bethune Public Welfare Foundation, proposed that on the occasion of the weakness of the intensive muscle, he hopes to take this opportunity to take this opportunity with government departments, medical institutions, academic organizations, experts and scholars, and call on the whole society to treat patients with severe muscle weak patients. Further attention and care, add confidence to the treatment and rehabilitation of patients with severe muscles, and respond to the goal of "Healthy China 2030".

On the day of the event, Bethune · Health Dream-Severe Muscle weak public welfare care activities were also launched. Lotic City linkages Beijing, Shanghai, Suzhou, and Haikou to form five city teams to combine public welfare and movement. Fire patient groups cheer for help. (Guangming Daily All Media Reporter Tian Yating)

- END -